A significant association between GH replacement and a higher risk for secondary neoplasia has been reported in some (52, 54), but not all (55, 61, 69, 70, 71), studies investigating health outcomes in childhood cancer survivors, as well as a meta-analysis from the Endocrine Society (61). Here, GH1 is linked to neoplasm.